IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Thonnard Serial No.: Unknown

Filed: Herewith

For: Novel Compounds

Group Art Unit No.: Unknown

Examiner: Unknown

BOX PCT/DO-EO

Commissioner for Patents Washington, DC 20231

"Express Mail" mailing label number EL 823 533 203 US

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 CFR § 1.10 on the date indicated above and addressed to: **BOX PCT/DO-EO**,

Commissioner for Patents, Washington, DC 20231, on December 13, 2001.

Colleen Hanagan

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.56

Applicants herein make available to the Patent and Trademark Office copies of the documents:

- listed on enclosed Form PTO/SB/08A/B (Formerly PTO-1449), in accordance with 37 CFR 1.98(a)(2); and
- listed on enclosed copies of Forms PTO-1449, PTO-892 or PTO/SB/08A/B, which forms recited the application information for applications to which this application claims priority under 35 U.S.C. §120, but have been edited to indicate the current application data. Pursuant to 37 CFR 1.98(d), NO COPIES OF THESE DOCUMENTS ARE ENCLOSED. The prior applications that provide the source of these documents are:

Serial No.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of this application. It is believed that the Examiner will concur with Applicant's belief that the foregoing references do not adversely affect the patentability of the subject matter presently claimed, taken alone or in combination.

It is requested that the listed references be included in the "References Cited" portion of any patent issuing from this application.

Under 37 CFR 1.97(i), Applicants understand that non-complying Information Disclosure Statements will be placed in the file but not considered by the Office, however, under Reply to Comment 8 of the Federal Register, page 2024, Applicants will be informed when information is not considered.

(1)	This Information Disclosure Statement is being filed:								
		within three months of the filing date of the patent application.							
	\boxtimes	within three months of the date of entry into the national stage as set forth in 37 CFR 1.491 of the international application.							
		before the mailing date of a first Office Action on the merits.							
		after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action under 37 CFR 1.116 or a Notice of Allowance under 37 CFR 1.311, and accordingly is accompanied by:							
		the Statement under 37 CFR 1.97(e) (see "Statement" below);							
	or								
		the Fee of \$180.00 set forth in 37 CFR 1.17(p); or							
		No fee is owed by the applicants.							
		after the mailing date of a Final Office Action under 37 CFR 1.116 or a Notice of Allowance under 37 CFR 1.311, and accordingly is accompanied by the Statement under 37 CFR 1.97(e), a Petition requesting consideration of the Information Disclosure Statement and the Petition Fee of \$130.00 set forth in 37 CFR 1.17(i)(1) (see "Statement," "Petition," and "Fees" below).							
(2)	Statement								
		The undersigned attorney hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.							
	(If this	box is checked, do not check any further Statement boxes.)							
or									
		The person signing immediately below hereby states that no item of information contained in the Information Disclosure was cited in a communication from a foreign patent office in a counterpart foreign patent application or, to the knowledge of the person signing after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement							

10/018561

PATENT
DOCKET NO. BM45396
JC13 Rec'd PCT/PTO 1 3 DEC 2001

The	person making the statement is:
	the inventor(s) who sign(s) below:
	Signature of the Inventor(s)
	Typed or Printed Name of the Inventor(s)
	or
	a person who is substantively involved in the preparation or prosecution of the application, and who is associated with the inventor(s), or with the assignee, or with anyone to whom there is an obligation to assign the application (37 CFR 1.565(c)) and who signs below:
	Signature of the Person(s)
	Typed or Printed Name of the Person
	Address of Person Signing
	or
	the undersigned attorney who signs on the basis of the information:
	supplied by the inventor(s).
	supplied by an individual designated in 37 CFR 1.56(c).
	in the attorney's file.
	Signature of the attorney
Petition	
	Applicants hereby petitions the Assistant Commissioner to consider
L	the references listed in this Information Disclosure Statement and on the enclosed Form PTO/SB/08A and 08B (Formerly PTO-1449), in the examination of the above-identified patent application. (This box checked only if a Final Office Action has issued)
(4) Fee	s
\boxtimes	No Fee is owed by the applicants.
	The IDS Fee of \$180.00 under 37 CFR 1.17(p) is enclosed herewith.
	The Petition Fee of \$130.00 under 37 CFR 1.17(i)(1) is enclosed herewith.

(3)

10/018561 PATENT DOCKET NO. BM45396

JC13 Rec'd PCT/PTO 1 3 DEC 2001

(5)	Metho	Method of Payment of Fees						
		Attached is a check in the amount of \$180.00.						
		Charge Account No. 50-0258 in the amount of \$ 180.00. (A duplicate of this request is attached).						
(6)	Autho	orization to Charge Additional Fees						
	\boxtimes	If any additional fees are owed in connection with this communication, please charge Deposit Account No. 50-0258.						
(7) Instructions as to Overpayment								
	\boxtimes	Please credit Account No. 50-0258 for any overpayment.						
		Please refund Dechert Price & Rhoads in the amount of \$						
A prompt an	d favoral	ble response is earnestly solicited.						
		Respectfully submitted,						
		Teresa O. Bittenbender Registration No. 47,425 Attorney for Applicant						

DECHERT 1717 Arch Street 4000 Bell Atlantic Tower Philadelphia, PA 19103 Fax: (215) 994-2222

Attn.: Teresa O. Bittenbender, Esq.

(215) 994-2213

124271.1.07

(Modifie	ed)	Information Disci Statement by Ap (use several Sheet	Trademark Off osure plicant	ice	Attorney Doc Serial No.: Applicant: Filing Date: Art No. Examiner	U T H U	nknown honnard lerewith nknown				
	_		U.S. PATE	NT DOC	UMENTS						
Exmr Initial		Patent Number	Issue Date	.	Patentee		Sub- Class	Filing Date If Appropriate			
ļ							ļ	_			
			+			_	 				
<u> </u>							 				
							-				
	t=i				·						
		FOREIGN PATEN	IT OR PUBLISH	IED FOR	EIGN PATENT	APPLICAT	ION				
Exmr Initial		Document Number	Publn Date	Cou	intry or Patent Office	Class	Sub- Class	Translation? Yes No			
		WO 95/09025	06.04.95	WIPC							
		EP 0 297291	30.05.88	EPO							
		EP 0 717106	19.06.96	EPO							
	<u> </u>			<u> </u>				,			
				<u> </u>							
OTHE	R D	OCUMENTS (Includ									
		De Mot, et al., from plant root June 1994, pp.	colonizing <i>Pseu</i>	ıdomona	s fluorescens"	, Microbiol					
	Murphy, et al., "The major heat-modifiable outer membrane protein CD is highly conserved among strains of <i>Branhamella catarrhalis</i> ", Molecular Biology, Vol. 10, No. 1, October 1, 1993, pp. 87-97, Accession No. XP000562828.										
	Yang, et al., "The major outer membrane protein, CD, extracted from Moraxella (Branhamella) catarrhalis is a potential vaccine antigen that induces bacterial antibodies", FEMS Immunology and Medical Microbiology, Vol 17., No. 3, March 1997, pp. 187-199, Accession No. XP-000960467.										
	Murphy, "Branhamella catarrhalis: Epidemiology, Surface Antigenic Structure, and Immune Response", Microbiological Reviews, Vol. 60, No. 2, June 1996, pp. 267-279, Accession No. XP-000857203.										
International Search Report from International Application No. PCT/EP00/05851.											
					· · · · · · · · · · · · · · · · · · ·						
Exami	ner		Da	Date Considered							

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO - 1449 [6-4])

- * Use publication date indicated on the patent or published application. 37 CFR 1.98(b).
- ** The place or publication refers to the name of the journal, magazine or other publication in which the article was published. Notice of January 9, 1992, 1135 O.G. 13 to 25 at 20.